



MASSACHUSETTS

Blue Cross Blue Shield of Massachusetts is an Independent Licensee of the Blue Cross and Blue Shield Association

Medical Policy

Artificial Intervertebral Disc: Cervical Spine

Table of Contents

- [Policy: Commercial](#)
- [Policy: Medicare](#)
- [Authorization Information](#)
- [Coding Information](#)
- [Description](#)
- [Policy History](#)
- [Information Pertaining to All Policies](#)
- [References](#)
- [Endnotes](#)

Policy Number: 585

BCBSA Reference Number: 7.01.108

LCD/NCD: N/A

Related Policies

Artificial Intervertebral Disc: Lumbar Spine, [#592](#)

Policy¹

Commercial Members: Managed Care (HMO and POS), PPO, and Indemnity Medicare HMO BlueSM and Medicare PPO BlueSM Members

Prior Authorization Request Form: Artificial Intervertebral Disc: Cervical Spine

This form must be completed and faxed to: Medical and Surgical: 1-888-282-0780; Medicare Advantage: 1-800-447-2994

[Click here for Artificial Intervertebral Disc: Cervical Spine Prior Authorization Request Form, #952](#)

Cervical disc arthroplasty may be considered **MEDICALLY NECESSARY** when **ALL** of the following criteria are met:

1. The device is approved by FDA;
2. The patient is skeletally mature;
3. The patient has intractable cervical radicular pain or myelopathy
 - a. which has failed at least 6 weeks of conservative nonoperative treatment, including active pain management program or protocol, under the direction of a physician, with pharmacotherapy that addresses neuropathic pain and other pain sources **AND** physical therapy; **OR**
 - b. if the patient has severe or rapidly progressive symptoms of nerve root or spinal cord compression requiring hospitalization or immediate surgical treatment;
4. Degeneration is documented by magnetic resonance imaging (MRI), computed tomography (CT), **OR** myelography;
5. Cervical degenerative disc disease is from C3-C7; **AND**
6. The patient is free from contraindication to cervical disc arthroplasty.

Simultaneous cervical disc arthroplasty at a second contiguous level may be considered **MEDICALLY NECESSARY** if the above criteria are met for each disc level, and the device is FDA-approved for 2 levels (ie, Mobi-C, Prestige LP).

Subsequent cervical disc arthroplasty at an adjacent level may be considered **MEDICALLY NECESSARY** when **ALL** of the following are met:

1. Criteria 1 to 6 above are met; **AND**
2. The device is FDA-approved for 2 levels; **AND**
3. The planned subsequent procedure is at a different cervical level than the initial cervical artificial disc replacement; **AND**
4. Clinical documentation that the initial cervical disc arthroplasty is fully healed.

Cervical disc arthroplasty is considered **INVESTIGATIONAL** for **ALL** other indications, including the following:

- Disc implantation at more than 2 levels
- Combined use of an artificial cervical disc and fusion
- Prior surgery at the treated level
- Previous fusion at another cervical level
- Translational instability
- Anatomical deformity (eg, ankylosing spondylitis)
- Rheumatoid arthritis or other autoimmune disease
- Presence of facet arthritis
- Active infection,
- Metabolic bone disease (eg, osteoporosis, osteopenia, osteomalacia)
- Neck or arm pain of unknown etiology
- Absence of neck and/or arm pain
- Progressive neurological deficit or deterioration
- Paget's disease, osteomalacia or any other metabolic bone disease
- Malignancy.
- There is radiological evidence of **ANY** of the following:
 - clinically significant cervical instability, such as kyphotic deformity or spondylolisthesis (e.g., > 3.5 mm sublaxation or > 11 degrees angulation)
 - significant cervical anatomical deformity or compromised vertebral bodies at the index level (e.g., ankylosing spondylitis, rheumatoid arthritis, or compromise due to current or past trauma)
 - spinal metastases.
- Non-FDA-approved cervical disc prosthesis.

Prior Authorization Information

Inpatient

- For services described in this policy, precertification/preauthorization **IS REQUIRED** for all products if the procedure is performed **inpatient**.

Outpatient

- For services described in this policy, see below for products where prior authorization **might be required** if the procedure is performed **outpatient**.

	Outpatient
Commercial Managed Care (HMO and POS)	Prior authorization is required .*
Commercial PPO and Indemnity	Prior authorization is required .*
Medicare HMO BlueSM	Prior authorization is required .*
Medicare PPO BlueSM	Prior authorization is required .*

***Prior Authorization Request Form: Artificial Intervertebral Disc: Cervical Spine**

This form **must** be completed and faxed to: **Medical and Surgical: 1-888-282-0780; Medicare Advantage: 1-800-447-2994**

[Click here for Artificial Intervertebral Disc: Cervical Spine Prior Authorization Request Form, #952](#)

CPT Codes / HCPCS Codes / ICD Codes

Inclusion or exclusion of a code does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage as it applies to an individual member.

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

The following codes are included below for informational purposes only; this is not an all-inclusive list.

The above medical necessity criteria MUST be met for the following codes to be covered for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
22856	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophyctomy for nerve root or spinal cord decompression and microdissection), single interspace, cervical
22858	Total disc arthroplasty (artificial disc), anterior approach, including discectomy with end plate preparation (includes osteophyctomy for nerve root or spinal cord decompression and microdissection); second level, cervical (List separately in addition to code for primary procedure)

ICD-10 Procedure Codes

ICD-10 PCS-procedure codes:	Code Description
0RR30JZ	Replacement of Cervical Vertebral Disc with Synthetic Substitute, Open Approach

The following CPT codes are considered investigational for Commercial Members: Managed Care (HMO and POS), PPO, Indemnity, Medicare HMO Blue and Medicare PPO Blue:

CPT Codes

CPT codes:	Code Description
22861	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; cervical
0098T	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, cervical (List separately in addition to code for primary procedure)

Description

Cervical Degenerative Disc Disease

Cervical degenerative disc disease is a manifestation of spinal spondylosis that causes deterioration of the intervertebral discs of the cervical spine. Symptoms of cervical degenerative disc disease include arm pain, weakness, and paresthesias associated with cervical radiculopathy. Disc herniation, osteophytes, kyphosis, or instability that compress the spinal cord can result in myelopathy, which is manifested by

subtle changes in gait or balance, and, in severe cases, leads to weakness in the arms or legs and numbness of the arms or hands. The prevalence of degenerative disc disease secondary to cervical spondylosis increases with age. An estimated 60% of individuals older than 40 years have radiographic evidence of cervical degenerative disc disease. By age 65, 95% of men and 70% of women have at least 1 degenerative change evident at the radiographic examination. It is estimated that approximately 5 million adults in the United States are disabled to an extent by spine-related disorders, although only a small fraction of those are clear candidates for spinal surgery.

Treatment

Anterior cervical discectomy and fusion has historically been considered the definitive surgical treatment for symptomatic degenerative disc disease of the cervical spine. The goals of anterior cervical discectomy and fusion are to relieve pressure on the spinal nerves (decompression) and to restore spinal column alignment and stability. Resolution of pain and neurologic symptoms may be expected in 80% to 100% of anterior cervical discectomy and fusion patients. Anterior cervical discectomy and fusion involves an anterolateral surgical approach, decompression of the affected spinal level, discectomy, and placement of a PEEK (polyetheretherketone) or titanium interbody cage plus autograft or allograft bone in the prepared intervertebral space to stimulate healing and eventual fusion between the vertebral endplates. A metal anterior cervical plate is attached to the adjoining vertebral bodies to stabilize the fusion site, maintain neck lordosis, and reduce the need for prolonged postoperative brace application that is needed following anterior cervical discectomy and fusion without an anterior plate. Although there may be slight differences between autograft and allograft sources in the postoperative rate of union, clinical studies have demonstrated similar rates of postoperative fusion (90%-100%) and satisfactory outcomes using either bone source. Studies have suggested that altered adjacent-segment kinematics following fusion may lead to adjacent-level degenerative disc disease and need for secondary surgery.

Cervical disc arthroplasty is proposed as an alternative to anterior cervical discectomy and fusion for patients with symptomatic cervical degenerative disc disease. In cervical disc arthroplasty, an artificial disc device is secured in the prepared intervertebral space rather than an interbody cage and/or bone. An anterior plate is not used to stabilize the adjacent vertebrae, and postsurgical external orthosis is usually not required. The cervical disc arthroplasty was designed to maintain anatomic disc space height, normal segmental lordosis, and physiological motion patterns at the index and adjacent cervical levels. The potential to reduce the risk of adjacent-level degenerative disc disease above or below a fusion site has been the major reason driving device development and use. Disc arthroplasty and anterior cervical discectomy and fusion have very similar surgical indications, primarily unremitting pain due to radiculopathy or myelopathy, weakness in the extremities, or paresthesia. However, the chief complaint in cervical disc arthroplasty candidates should be radicular or myelopathic symptoms in the absence of significant spondylosis or spondylolisthesis.

Summary

Several prosthetic devices are currently available for cervical disc arthroplasty. Cervical disc arthroplasty is proposed as an alternative to anterior cervical discectomy and fusion for patients with symptomatic cervical degenerative disc disease.

For individuals who have cervical radicular pain or myelopathy who receive single-level cervical disc arthroplasty, the evidence includes randomized controlled trials (RCTs) and meta-analyses of randomized controlled trials. Relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. At 2-year follow-up, trials of all artificial cervical discs met noninferiority criteria compared to anterior cervical discectomy and fusion. Mid-term outcomes have been reported on five devices (Prestige ST, ProDisc-C, Bryan, Mobi-C, PCM [Porous Coated Motion]). At 4 to 5 years, the trial results have been consistent with the continued noninferiority of cervical disc arthroplasty for clinical outcomes and lower cumulative reoperation rates. Seven-year follow-up of the Prestige and ProDisc-C pivotal trials continue to show lower secondary surgery rates, although this is not a consistent finding in other reports. Serious adverse events appear to be uncommon. Heterotopic ossification can occur in a substantial proportion of spinal segments with artificial intervertebral discs but does not appear to lead to a decline in clinical outcomes. The evidence to date shows outcomes that are at least as good as the

standard treatment of anterior cervical discectomy and fusion. There have been no safety signals with discs approved by the U.S. Food and Drug Administration (FDA) for single-level cervical disc arthroplasty. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

For individuals who have cervical radicular pain or myelopathy who receive 2-level cervical disc arthroplasty of the cervical spine, the evidence includes RCTs. The relevant outcomes are symptoms, morbid events, functional outcomes, quality of life, and treatment-related morbidity. FDA approval for the Prestige LP™ was based on superiority to 2-level anterior cervical discectomy and fusion in overall success at 2 years. The increase in overall success rates at 2 years has been maintained for those patients who have reached the 10-year follow-up. At 2 and 4 year follow-ups, the first artificial cervical disc approved for 2 levels (Mobi-C) was found to be superior to anterior cervical discectomy and fusion for Neck Disability Index scores, Neck Disability Index success rates, reoperation rates, and overall success composite outcome. At 5 years, trial results were consistent with the continued superiority of 2-level cervical disc arthroplasty for clinical outcomes and lower cumulative reoperation rates. Adjacent-segment degeneration with Mobi-C was found in a significantly lower percentage of patients compared with 2-level anterior cervical discectomy and fusion patients. Based on this evidence, it can be concluded that 2 level cervical disc arthroplasty with either of these FDA approved discs is at least as beneficial as the established alternative. The evidence is sufficient to determine that the technology results in a meaningful improvement in the net health outcome.

Policy History

Date	Action
6/2020	BCBSA National medical policy review. Terminology clarified from artificial intervertebral disc arthroplasty of the cervical spine to cervical disc arthroplasty.
1/2020	Clarified coding information.
5/2019	BCBSA National medical policy review. Description, summary and references updated. Policy statements unchanged.
8/2018	Outpatient prior authorization is required. Effective 8/1/2018.
5/2018	Clarified coding information
7/2017	Clarified coding information.
5/2017	New references added from BCBSA National medical policy.
2/2017	BCBSA National medical policy review. Considered medically necessary for 2-level cervical disc replacement with a device that is FDA-approved for 2-levels (ie, Mobi-C, Prestige LP). Effective 2/1/2017.
12/2015	BCBSA National medical policy review. New medically necessary and investigational indications described. Effective 12/1/2015.
1/2015	Clarified coding information.
8/2014	Coding information clarified.
11/2013	Medically necessary indications described. Effective 11/1/2013.
11/2011-4/2012	Medical policy ICD 10 remediation: Formatting, editing and coding updates. No changes to policy statements.
1/2011	Updated - Medical Policy Group – Neurology and Neurosurgery. No changes to policy statements.
10/20/2010	Medical Policy 585 effective 10/20/2010.

Information Pertaining to All Blue Cross Blue Shield Medical Policies

Click on any of the following terms to access the relevant information:

[Medical Policy Terms of Use](#)

[Managed Care Guidelines](#)

[Indemnity/PPO Guidelines](#)

[Clinical Exception Process](#)

[Medical Technology Assessment Guidelines](#)

References

1. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2007;Volume 22:Tab 12.
2. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2009;Volume 24:Tab 3.
3. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disease of the cervical spine. TEC Assessments. 2011;Volume 26:Tab 5.
4. Blue Cross and Blue Shield Association Technology Evaluation Center (TEC). Artificial intervertebral disc arthroplasty for treatment of degenerative disc disease of the cervical spine. TEC Assessments. 2013;Volume 28:Tab 13.
5. Vernon H, Mior S. The Neck Disability Index: a study of reliability and validity. *J Manipulative Physiol Ther.* Sep 1991;14(7):409-415. PMID 1834753
6. Hu Y, Lv G, Ren S, et al. Mid- to long-term outcomes of cervical disc arthroplasty versus anterior cervical discectomy and fusion for treatment of symptomatic cervical disc disease: a systematic review and meta-analysis of eight prospective randomized controlled trials. *PLoS One.* Feb 2016;11(2):e0149312. PMID 26872258
7. Burkus JK, Traynelis VC, Haid RW, Jr., et al. Clinical and radiographic analysis of an artificial cervical disc: 7- year follow-up from the Prestige prospective randomized controlled clinical trial: Clinical article. *J Neurosurg Spine.* Oct 2014;21(4):516-528. PMID 25036218
8. Sasso RC, Anderson PA, Riew KD, et al. Results of cervical arthroplasty compared with anterior discectomy and fusion: four-year clinical outcomes in a prospective, randomized controlled trial. *J Bone Joint Surg Am.* Sep 21 2011;93(18):1684-1692. PMID 21938372
9. Phillips FM, Geisler FH, Gilder KM, et al. Long-term outcomes of the US FDA IDE prospective, randomized controlled clinical trial comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion. *Spine (Phila Pa 1976).* May 15 2015;40(10):674-683. PMID 25955086
10. Coric D, Kim PK, Clemente JD, et al. Prospective randomized study of cervical arthroplasty and anterior cervical discectomy and fusion with long-term follow-up: results in 74 patients from a single site. *J Neurosurg Spine.* Jan 2013;18(1):36-42. PMID 23140129
11. Davis RJ, Nunley PD, Kim KD, et al. Two-level total disc replacement with Mobi-C cervical artificial disc versus anterior discectomy and fusion: a prospective, randomized, controlled multicenter clinical trial with 4-year follow- up results. *J Neurosurg Spine.* Jan 2015;22(1):15-25. PMID 25380538
12. Hisey MS, Bae HW, Davis RJ, et al. Prospective, randomized comparison of cervical total disk replacement versus anterior cervical fusion: results at 48 months follow-up. *J Spinal Disord Tech.* May 2015;28(4):E237-243. PMID 25310394
13. Janssen ME, Zigler JE, Spivak JM, et al. ProDisc-C Total Disc replacement versus anterior cervical discectomy and fusion for single-level symptomatic cervical disc disease: seven-year follow-up of the prospective randomized U.S. Food and Drug Administration Investigational Device Exemption Study. *J Bone Joint Surg Am.* Nov 4 2015;97(21):1738-1747. PMID 26537161
14. Zhang HX, Shao YD, Chen Y, et al. A prospective, randomised, controlled multicentre study comparing cervical disc replacement with anterior cervical decompression and fusion. *Int Orthop.* Dec 2014;38(12):2533-2541. PMID 25209344
15. Latka D, Kozłowska K, Miekisiak G et al. Safety and efficacy of cervical disc arthroplasty in preventing the adjacent segment disease: a meta-analysis of mid- to long-term outcomes in prospective, randomized, controlled multicenter studies. *Ther Clin Risk Manag.* 2019;15:531-539. PMID 30992666
16. Mummaneni PV, Burkus JK, Haid RW, et al. Clinical and radiographic analysis of cervical disc arthroplasty compared with allograft fusion: a randomized controlled clinical trial. *J Neurosurg Spine.* Mar 2007;6(3):198-209. PMID 17355018
17. Gornet MF, Burkus JK, Shaffrey ME, et al. Cervical disc arthroplasty with PRESTIGE LP disc versus anterior cervical discectomy and fusion: a prospective, multicenter investigational device exemption study. *J Neurosurg Spine.* Jul 31 2015:1-16. PMID 26230424
18. Murrey D, Janssen M, Delamarter R, et al. Results of the prospective, randomized, controlled multicenter Food and Drug Administration investigational device exemption study of the ProDisc-C

- total disc replacement versus anterior discectomy and fusion for the treatment of 1-level symptomatic cervical disc disease. *Spine J.* Apr 2009;9(4):275-286. PMID 18774751
19. Heller JG, Sasso RC, Papadopoulos SM, et al. Comparison of BRYAN cervical disc arthroplasty with anterior cervical decompression and fusion: clinical and radiographic results of a randomized, controlled, clinical trial. *Spine (Phila Pa 1976)*. Jan 15 2009;34(2):101-107. PMID 19112337
 20. U.S. Food and Drug Administration (FDA). Summary of Safety and Effectiveness Data (SSED): Mobi-C. 2013; https://www.accessdata.fda.gov/cdrh_docs/pdf11/P110002b.pdf. Accessed March 9, 2020.
 21. Phillips FM, Lee JY, Geisler FH, et al. A prospective, randomized, controlled clinical investigation comparing PCM cervical disc arthroplasty with anterior cervical discectomy and fusion: 2-year results from the US FDA IDE clinical trial. *Spine (Phila Pa 1976)*. Jul 1 2013;38(15):E907-918. PMID 23591659
 22. Vaccaro A, Beutler W, Peppelman W, et al. Clinical outcomes with selectively constrained SECURE-C cervical disc arthroplasty: two-year results from a prospective, randomized, controlled, multicenter investigational device exemption study. *Spine (Phila Pa 1976)*. Dec 15 2013;38(26):2227-2239. PMID 24335629
 23. U.S. Food and Drug Administration. Summary of Safety and Effectiveness: M6-C Artificial Cervical Disc. 2019. <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfma/pma.cfm?id=P170036>. Accessed March 10, 2020
 24. Burkus JK, Haid RW, Traynelis VC, et al. Long-term clinical and radiographic outcomes of cervical disc replacement with the Prestige disc: results from a prospective randomized controlled clinical trial. *J Neurosurg Spine*. Sep 2010;13(3):308-318. PMID 20809722
 25. Delamarter RB, Murrey D, Janssen ME, et al. Results at 24 months from the prospective, randomized, multicenter Investigational Device Exemption trial of ProDisc-C versus anterior cervical discectomy and fusion with 4-year follow-up and continued access patients. *SAS J.* Jan 2010;4(4):122-128. PMID 25802660
 26. Zigler JE, Delamarter R, Murrey D, et al. ProDisc-C and anterior cervical discectomy and fusion as surgical treatment for single-level cervical symptomatic degenerative disc disease: five-year results of a Food and Drug Administration study. *Spine (Phila Pa 1976)*. Feb 1 2013;38(3):203-209. PMID 23080427
 27. Delamarter RB, Zigler J. Five-year reoperation rates, cervical total disc replacement versus fusion, results of a prospective randomized clinical trial. *Spine (Phila Pa 1976)*. Nov 2 2013;38(9):711-717. PMID 23124255
 28. Lavelle WF, Riew KD, Levi AD et al. Ten-year Outcomes of Cervical Disc Replacement With the BRYAN Cervical Disc: Results From a Prospective, Randomized, Controlled Clinical Trial. *Spine*. 2019 May;44(9). PMID 30325888
 29. Hisey MS, Bae HW, Davis R, et al. Multi-center, prospective, randomized, controlled investigational device exemption clinical trial comparing Mobi-C Cervical Artificial Disc to anterior discectomy and fusion in the treatment of symptomatic degenerative disc disease in the cervical spine. *Int J Spine Surg*. Feb 2014;8. PMID 25694918
 30. Hisey MS, Zigler JE, Jackson R, et al. Prospective, randomized comparison of one-level Mobi-C Cervical Total Disc replacement vs. anterior cervical discectomy and fusion: results at 5-year follow-up. *Int J Spine Surg*. 2016;10:10. PMID 27162712
 31. U.S. Food and Drug Administration. Summary of Safety and Effectiveness: Prestige LP Cervical Disc. PMA Number P090029/S003. 2016; https://www.accessdata.fda.gov/cdrh_docs/pdf9/p090029s003b.pdf. Accessed March 10, 2020.
 32. Davis RJ, Kim KD, Hisey MS, et al. Cervical total disc replacement with the Mobi-C cervical artificial disc compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled multicenter clinical trial. *J Neurosurg Spine*. Nov 2013;19(5):532-545. PMID 24010901
 33. Radcliff K, Coric D, Albert T. Five-year clinical results of cervical total disc replacement compared with anterior discectomy and fusion for treatment of 2-level symptomatic degenerative disc disease: a prospective, randomized, controlled, multicenter investigational device exemption clinical trial. *J Neurosurg Spine*. Aug 2016;25(2):213-224. PMID 27015130
 34. Bae HW, Kim KD, Nunley PD, et al. Comparison of clinical outcomes of 1- and 2-level total disc replacement: four-year results from a prospective, randomized, controlled, multicenter IDE clinical trial. *Spine (Phila Pa 1976)*. Jun 1 2015;40(11):759-766. PMID 25785955

35. Huppert J, Beaurain J, Steib JP, et al. Comparison between single- and multi-level patients: clinical and radiological outcomes 2 years after cervical disc replacement. *Eur Spine J.* Sep 2011;20(9):1417-1426. PMID 21336970
36. Staub LP, Ryser C, Roder C, et al. Total disc arthroplasty versus anterior cervical interbody fusion: use of the Spine Tango registry to supplement the evidence from randomized control trials. *Spine J.* Feb 2016;16(2):136- 145. PMID 26674445
37. MacDowall A, Skeppholm M, Lindhagen L et al. Artificial disc replacement versus fusion in patients with cervical degenerative disc disease with radiculopathy: 5-year outcomes from the National Swedish Spine Register. *J Neurosurg Spine.* 2018 Nov;30(2). PMID 30485205
38. Chen J, Wang X, Bai W, et al. Prevalence of heterotopic ossification after cervical total disc arthroplasty: a meta- analysis. *Eur Spine J.* Apr 2012;21(4):674-680. PMID 22134486
39. Nunley PD, Cavanaugh DA, Kerr EJ et al. Heterotopic Ossification After Cervical Total Disc Replacement at 7 Years-Prevalence, Progression, Clinical Implications, and Risk Factors. *Int J Spine Surg.* 2018 Jun;12(3). PMID 30276092
40. North American Spine Society. NASS coverage policy recommendations: Cervical artificial disc replacement. 2015; <https://www.spine.org/PolicyPractice/CoverageRecommendations/AboutCoverageRecommendations.aspx>. Accessed March 10, 2020.
41. National Institute for Health and Care Excellence (NICE). Prosthetic intervertebral disc replacement in the cervical spine [IPG341]. 2010; <https://www.nice.org.uk/guidance/ipg341>. Accessed March 10, 2020.
42. Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) for Lumbar Artificial DISC Replacement (LADR) (150.10). 2007; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=313&ncdver=2&CoverageSelection=National&KeyWord=disc&KeyWordLookUp=Title&Key WordSearchType=And&from2=search.asp&bc=gAAAACAAAAAAAA%3d%3d&>. Accessed March 10 2020.

Endnotes

¹ Based on expert opinion